Resources

Selected
  • RSV
  • RSV (Respiratory syncytial virus)
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

71 results found

2026 ∙ Du, J. Li, S. Hung, I. F. N. Wu, J. T. Leung, K.

Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025

  • Pregnant women
  • Older adults
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2026 ∙ Trusinska, D. Lee, B. Ferdous, S. Lansbury, L. Burden, C. Anand, A. Stowe, J. Mensah, A. Lim, W. Marsh, K. Gibbons, C. Shi, T.

Real-world evidence on RSV vaccine uptake, effectiveness, and safety in older adults: a systematic review and meta-analysis

  • Adults
  • Older adults
  • RSV (Respiratory syncytial virus)
  • Coverage
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
High
2026 ∙ Public Health Agency of Canada

Updated guidance to protect infants and children from respiratory syncytial virus (RSV) disease: use of monoclonal antibodies (nirsevimab and clesrovimab) and the RSVpreF vaccine

  • Americas
  • Canada
  • children
  • infants
  • RSV (Respiratory syncytial virus)
Download:
2026 ∙ Public Health Agency of Canada

Updated guidance on respiratory syncytial virus (RSV) vaccines for older adults and for adults at high risk of severe RSV disease

  • Americas
  • Canada
  • older adults
  • adults
  • RSV (Respiratory syncytial virus)
Download:
2026

Respiratory syncytial virus (RSV): vaccination for older adults

  • Europe
  • United Kingdom
  • RSV (Respiratory syncytial virus)
Download:
2025 ∙ Zhu, B. Lu, Y. Zhou, Y. Li, W. Wu, Y. Bao, Y. Lu, Y.

Economic evaluations of RSV preventive strategies: a systematic review of cost-effectiveness and modeling approaches

  • Newborn
  • Children
  • Older adults
  • RSV (Respiratory syncytial virus)
  • Economic aspects
  • Modeling
  • Administration
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Saif-Ur-Rahman, K. King, C. Whelan, S. O. Blair, M. Donohue, S. Madden, C. Kothari, K. Sommer, I. Harder, T. Dauby, N. et al.,

Efficacy and safety of respiratory syncytial virus vaccines

  • All age groups
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Moderate
2025 ∙ Alandijany, T. A. Qashqari, F. S.

Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia

  • All age groups
  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Chen, J. Yang, C. Lin, W. Cheng, X. He, H. Li, X. Yu, J.

Immunogenicity, Safety, and Protective Efficacy of Mucosal Vaccines Against Respiratory Infectious Diseases: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Influenza
  • RSV (Respiratory syncytial virus)
  • Pertussis
  • Tuberculosis
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Amare, S. N. Yee, K. C. Leung, M. Naunton, M. Bushell, M.

Impact of pharmacist-led interventions on COVID-19, herpes zoster, influenza, pneumococcal, and respiratory syncytial virus vaccines uptake in people aged 60 years and older: Systematic review and meta-analysis

  • Adults
  • Older adults
  • Herpes zoster
  • Influenza
  • Pneumococcal disease
  • RSV (Respiratory syncytial virus)
  • COVID-19
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
Loading...